In a report released today, Ryan Zimmerman from BTIG upgraded Organogenesis Holdings (ORGO – Research Report) to a Buy, with a price target of $10.00. The company’s shares closed today at $3.44.
According to TipRanks, Zimmerman is a 5-star analyst with an average return of 11.3% and a 50.20% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Organogenesis Holdings, Alcon, and Treace Medical Concepts.
Organogenesis Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $10.00.
See Insiders’ Hot Stocks on TipRanks >>
ORGO market cap is currently $420M and has a P/E ratio of 33.53.
Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ORGO in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Organogenesis Holdings, Inc. is a regenerative medical company. It focuses on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.
Read More on ORGO:
- Organogenesis Holdings Inc. Reports First Quarter 2023 Financial Results
- Is ORGO a Buy, Before Earnings?
- Organogenesis President, CEO Gillheeney, Sr. elected as chair of the board
- Organogenesis President and Chief Executive Officer Gary S. Gillheeney, Sr. Elected Chair of the Board of Directors
- Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2023 Financial Results on May 10, 2023
